Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid.
Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201.
BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate..
Price and Volume | |
---|---|
Volume | |
Ten Day Average Volume | 698.6K |
Three Month Average Volume | 26.1M |
High Low | |
Fifty-Two Week High | 49.5 USD |
Fifty-Two Week Low | 16.95 USD |
Fifty-Two Week High Date | 27 Feb 2024 |
Fifty-Two Week Low Date | 23 Oct 2023 |
Price and Volume | |
Current Price | 26.68 USD |
Beta | 2 |
Relative Price Change | |
Four Week Relative Price Change | -7.93% |
Thirteen Week Relative Price Change | 4.65% |
Twenty-Six Week Relative Price Change | -39.09% |
Fifty-Two Week Relative Price Change | -8.15% |
Year-to-Date Relative Price Change | -17.23% |
Price Change | |
One Day Price Change | -0.60% |
Thirteen Week Price Change | 12.01% |
Twenty-Six Week Price Change | -33.03% |
Five Day Price Change | -0.48% |
Fifty-Two Week Price Change | 15.10% |
Year-to-Date Price Change | -1.98% |
Month-to-Date Price Change | -15.68% |
Per Share Data | |
---|---|
Book Value | |
Book Value Per Share (Last Fiscal Year) | 12.0213 USD |
Book Value Per Share (Most Recent Quarter) | 10.36695 USD |
Tangible Book Value Per Share (Last Fiscal Year) | 12.0213 USD |
Tangible Book Value Per Share (Most Recent Quarter) | 10.36695 USD |
EBITD | |
EBITD Per Share (Trailing Twelve Months) | -2.01127 USD |
Revenue | |
Revenue Per Share (Last Fiscal Year) | 4.89566 USD |
Revenue Per Share (Trailing Twelve Months) | 4.35355 USD |
Dividend | |
Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
Dividend Per Share (Trailing Twelve Months) | 0 USD |
Dividend Per Share (5 Year) | -99999.99 USD |
Earnings Per Share | |
Excluding Extraordinary Items (Last Fiscal Year) | -1.71774 USD |
Excluding Extraordinary Items (Trailing Twelve Months) | -1.76468 USD |
Normalized (Last Fiscal Year) | -1.71774 USD |
Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.71774 USD |
Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.76468 USD |
Including Extraordinary Items (Last Fiscal Year) | -1.71774 USD |
Including Extraordinary Items (Trailing Twelve Months) | -1.76468 USD |
Cash | |
Cash Per Share (Last Fiscal Year) | 14.57601 USD |
Cash Per Share (Most Recent Quarter) | 12.23706 USD |
Cash Flow Per Share (Last Fiscal Year) | -1.45836 USD |
Cash Flow Per Share (Trailing Twelve Months) | -1.49975 USD |
Free Cash Flow Per Share (Trailing Twelve Months) | -1.89424 USD |
Margins | |
---|---|
Cash Flow Revenue | |
Cash Flow Revenue (5 Year) | -106 |
Cash Flow Revenue (Trailing Twelve Months) | -44 |
Pretax Margin | |
Pretax Margin (Trailing Twelve Months) | -40.16% |
Pretax Margin (Last Fiscal Year) | -34.73% |
Pretax Margin (5 Year) | -210.98% |
Gross Margin | |
Gross Margin (Last Fiscal Year) | -99,999.99% |
Gross Margin (Trailing Twelve Months) | -99,999.99% |
Gross Margin (5 Year) | -99,999.99% |
Operating Margin | |
Operating Margin (Last Fiscal Year) | -46.73% |
Operating Margin (Trailing Twelve Months) | -52.31% |
Operating Margin (5 Year) | -227.38% |
Net Profit Margin | |
Net Profit Margin (Last Fiscal Year) | -35.09% |
Net Profit Margin (Trailing Twelve Months) | -40.56% |
Net Profit Margin (5 Year) | -211.96% |
Growth | |
---|---|
Book Value | |
Book Value Per Share (5 Year) | 32.38% |
Tangible Book Value (5 Year) | 48.91% |
Free Operating Cash Flow | |
Free Operating Cash Flow (5 Year) | -99,999.99% |
Revenue | |
Revenue Change MRQ vs 1 Year Ago | -41.48% |
Revenue Growth (3 Year) | -99,999.99% |
Revenue Change (Trailing Twelve Months) | 339.83% |
Revenue Per Share Growth | -99,999.99% |
Revenue Growth (5 Year) | 2,406.00% |
Capital Spending Debt | |
Capital Spending (5 Year) | 20.78% |
Total Debt (5 Year) | -48.80% |
Dividends | |
Dividend Growth (3 Year) | -99,999.99% |
Earnings Per Share | |
EPS Change MRQ vs 1 Year Ago | -2.01% |
EPS Change (Trailing Twelve Months) | 60.95% |
EPS Growth (3 Year) | -99,999.99% |
EPS Growth (5 Year) | -99,999.99% |
EBITDA | |
EBITDA (5 Year) | -99,999.99% |
EBITDA (5 Year Interim) | -99,999.99% |
Net Profit Margin | |
Net Profit Margin Growth (5 Year) | -99,999.99% |
Valuation | |
---|---|
Total Price to Book | |
Price to Tangible Book (Last Fiscal Year) | 2 |
Price to Tangible Book (Most Recent Quarter) | 3 |
Price to Free Cash Flow | |
Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
Net Debt | |
Net Debt (Most Recent Quarter) | -1,008,165,000 |
Net Debt (Last Fiscal Year) | -1,189,392,000 |
Price to Sales | |
Price to Sales (Last Fiscal Year) | 6 |
Price to Sales (Trailing Twelve Months) | 6 |
Price to Earnings | |
PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
PE Normalized (Last Fiscal Year) | -100,000 |
PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
Dividends | |
Dividend Yield (5 Year) | -99,999.99% |
Dividend Yield | -99,999.99% |
Current Dividend Yield | 0.00% |
Price to Book | |
Price to Book (Last Fiscal Year) | 2 |
Price to Book (Most Recent Quarter) | 3 |
Financial Strength | |
---|---|
Debt to Equity | |
Long Term Debt to Equity (Last Fiscal Year) | 0 |
Long Term Debt to Equity (Most Recent Quarter) | 0 |
Payout Ratio | |
Payout Ratio (Last Fiscal Year) | -99,999.99% |
Payout Ratio (Trailing Twelve Months) | -99,999.99% |
Quick Ratio | |
Quick Ratio (Last Fiscal Year) | -100,000 |
Quick Ratio (Most Recent Quarter) | -100,000 |
Enterprise Value | |
Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
Current Ratio | |
Current Ratio (Last Fiscal Year) | 6 |
Current Ratio (Most Recent Quarter) | 6 |
Free Cash Flow | |
Free Cash Flow (Last Fiscal Year) | -182,927,000 |
Free Cash Flow (Trailing Twelve Months) | -153,403,000 |
Net Interest Coverage | |
Net Interest Coverage (Last Fiscal Year) | -100,000 |
Net Interest Coverage (Trailing Twelve Months) | -100,000 |
Total Debt to Equity | |
Total Debt to Equity (Last Fiscal Year) | 0 |
Total Debt to Equity (Most Recent Quarter) | 0 |
Management Effectiveness | |
---|---|
Return on Assets | |
Return on Assets (Last Fiscal Year) | -9.46% |
Return on Assets (Trailing Twelve Months) | -10.94% |
Return on Assets (5 Year) | -24.54% |
Return on Equity | |
Return on Equity (Last Fiscal Year) | -15.46% |
Return on Equity (Trailing Twelve Months) | -17.17% |
Return on Equity (5 Year) | -52.99% |
Return on Investment | |
Return on Investment (Last Fiscal Year) | -11.17% |
Return on Investment (Trailing Twelve Months) | -12.84% |
Return on Investment (5 Year) | -29.26% |